RSV vaccine trial enrolling 6- to 24-months-old childrenJun. 1, 2022, 9:25 AM
Vanderbilt researchers are enrolling healthy 6 to 24-month-old children to participate in a Respiratory Syncytial Virus (RSV) vaccine research study. RSV is a virus that causes respiratory illness in children like croup, pneumonia, and wheezing.
The purpose of this research study is to look at the safety (side effects) of this study vaccine. In addition, scientists will look at the antibody response (germ fighters) to the vaccine in healthy children. This study vaccine is given as nose drops at no cost to you.
Your child may be eligible if:
- Between the ages of ≥ 6 months and <25 months at the time of vaccination
- Born > 34 weeks gestational age
- Up to date on vaccinations per CDC guidelines
- Has never been diagnosed with RSV
- 3-7 study visits to the Vanderbilt Children’s Hospital, Clinical Research Center
- Vaccine (nose drops) once
- Blood collection
- Nose swabs
- Phone call check-ins with a study nurse
Experienced Vanderbilt pediatric nurses lead the study visits and may be able to schedule visits to accommodate your calendar.
Once your child completes the study, you will be compensated for your time.
For more information or to see if your child qualifies, please contact:
Samantha Economos CPNP-PC